Viewing Study NCT05493410



Ignite Creation Date: 2024-05-06 @ 5:57 PM
Last Modification Date: 2024-10-26 @ 2:39 PM
Study NCT ID: NCT05493410
Status: COMPLETED
Last Update Posted: 2022-08-09
First Post: 2022-08-05

Brief Title: EFFECTS OF INSPIRATORY MUSCLE TRAINING IN POST-COVID-19 PATIENTS
Sponsor: University Vila Velha
Organization: University Vila Velha

Study Overview

Official Title: EFFECTS OF INSPIRATORY MUSCLE TRAINING ON INSPIRATORY MUSCLE STRENGTH AND ENDURANCE AND FUNCTIONAL CAPACITY OF POST-COVID-19 PATIENTS
Status: COMPLETED
Status Verified Date: 2022-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: COVID-19 is an infectious disease caused by the SARS-CoV-2 virus which had its first case identified in December 2019 in Wuhan China The disease can cause death and collapse in health systems in addition to increasingly prevalent sequelae Among the persistent symptoms presented by patients in the post-COVID-19 phase we highlight the respiratory ones The diaphragm - the main muscle of respiration - can also undergo structural and functional changes resulting from SARS-CoV-2 infection This finding is related to some respiratory sequelae of the disease such as severe myopathy of the diaphragm with weakness and decreased endurance of the inspiratory muscles dyspnea fatigue and failure in ventilatory weaning Considering that COVID-19 can affect the respiratory muscles of afflicted individuals it is reasonable to assume that inspiratory muscle training should improve inspiratory muscle weakness and endurance and the functional capacity of individuals who had symptomatic COVID-19 Objective To evaluate the effect of inspiratory muscle training on inspiratory muscle strength and endurance and on the functional capacity of individuals afflicted by COVID-19 Methods This controlled and randomized clinical trial will be conducted according to the guidelines of the Vila Velha University Ethics Committee CEP-UVV The sample will consist of individuals with a positive diagnosis for SARS-CoV-2 infection assessed by means of the reverse transcriptase reaction followed by the polymerase chain reaction RT-PCR and who have already undergone the period of active infection These individuals will be invited to participate in the study as soon as they are evaluated by the cardiopulmonary rehabilitation service Those who meet all the inclusion criteria agree to participate and sign the free and informed consent form FICF will be randomly assigned to two groups the control group CG n 21 and the treatment group TG n 21 The initial evaluation will consist of anamnesis measurement of indirect blood pressure heart rate and peripheral oxygen saturation by portable pulse oximeter analysis of maximum inspiratory pressure MIP dynamic inspiratory muscle strength index S-Index and endurance of the inspiratory muscles - which will be collected using a digital training device PowerBreathe KH2 in addition to functional assessment through the 1-minute sit-to-stand test The reassessment will take place six weeks after the start of the program and the same data will be collected at the participants homes Both groups will undergo the rehabilitation protocol consisting of muscle strengthening and aerobic training with individual assessment of exercise intensity The treated group will undergo inspiratory muscle training through linear pressure load using the POWERbreathe Classic Medic device to perform two sets of 30 repetitions daily for six weeks The same physical therapist will oversee the training sessions of all patients Statistical analysis Data normality will be tested using the Shapiro-Wilk test To analyze the differences between groups we will use the t-test for parametric data and the Wilcoxon test for non-parametric data The level of significance will be set at 5 p 005 Data will be analyzed using the SPSS 80 software and the results expressed as mean standard deviation or median and interquartile range
Detailed Description: This randomized controlled clinical trial will be carried out according to the ethical standards for research with human beings and shall be previously approved by the human research ethics committee CEP-UVV participants will have to sign the free and informed consent form FICF

The sample will consist of individuals with a positive diagnosis for SARS-CoV-2 infection assessed by means of the reverse transcriptase reaction followed by the polymerase chain reaction RT-PCR and who have already undergone the period of active infection The active infection period comprises 14 days from the onset of symptoms for those who have not been hospitalized and 21 days for those who have been hospitalized These individuals will be invited to participate in the research as soon as they are evaluated by the cardiopulmonary rehabilitation service Those who meet all the inclusion criteria agree to participate and sign the FICF will be randomly assigned to two groups the control group CG and the treatment group TG The block randomization scheme will be generated using the randomizationcom website httpwwwrandomizationcom The allocation of participants will be carried out by a different researcher from the one who will treat the patients thus ensuring blinding In addition the researchers who will collect and analyze the data will be different and both blind to the experimental groups and types of intervention

Regarding the sample size as the study was designed to detect a mean difference of 20 cmH2O in MIP between groups with a standard deviation of 15 Newall Stockley 2005 a 95 confidence level and a significance level of 005 two-tailed α we calculated that each group should contain 15 subjects Considering the possibility of a sample loss of 20-25 42 individuals will be recruited 21 per group Newall 2005

The initial assessment will be carried out by the cardiopulmonary rehabilitation service at home in which the following data will be collected anamnesis blood pressure BP measurement by digital sphygmomanometer Omron HEM 705CP Tokyo Japão heart rate HR and peripheral oxygen saturation SpO2 by the portable pulse oximeter G-Tech Oled Graph Beijing Choice Electronic Technology Co Ltd Beijing China MIP dynamic inspiratory muscle strength S-Index and inspiratory muscle endurance analyses using the POWERbreathe K-series KH2 POWERbreathe International Ltd Warwickshire United Kingdom and functional assessment through the 1-minute sit-to-stand test 1-min STS

The reassessment will take place six weeks after the start of the program and the same data will be collected at the participants homes

The primary outcome of the study to evaluate inspiratory muscles will be MIP while S-Index endurance and functional capacity will be secondary outcomes

EVALUATION PROCEDURES

1-MINUTE SIT-TO-STAND TEST This test assesses the functional capacity of individuals with different types of diseases or dysfunctions This standardized assessment is performed in an armless 46-cm-high chair The individual evaluated receives the verbal command to get up and sit down from the chair as many times as possible within a 1-minute interval The main outcome of the test is how many times the individual sat and stood up secondarily vital and perceived exertion data are recorded before during and immediately after the test is performed

MEASUREMENT OF BP HR AND SPO2 BP will be measured using a digital sphygmomanometer Omron HEM 705CP Tokyo Japan The patient will remain seated for five minutes in a comfortable chair with the back relaxed and supported on the backrest legs uncrossed left arm supported on the table and free of clothes at arm height The patient cannot drink alcohol have smoked or exercised 30 minutes before the measurement and the bladder must be empty Three measurements will be taken with a 2-min interval between them the first will be discarded and the BP value obtained by the average between the last two measurements

HR and SpO2 will be measured using the portable pulse oximeter G-Tech Oled Graph Beijing Choice Electronic Technology Co Ltd Beijing China Pulse oximetry measures how much oxygen the blood is carrying Through a small device called a pulse oximeter the blood oxygen level can be measured without the need for an arterial blood puncture To measure oxygen beams of light produced by the device pass through the blood on the finger and are read to calculate the percentage of oxygen transport This method also measures HR The accuracy of the oximeter is 2 above or 2 below the saturation that can be obtained by an arterial blood gas test To obtain a better reading the patient will be instructed to keep the hand warm relaxed kept below the level of the heart and not to use fake nails andor nail polish

MIP S-INDEX AND ENDURANCE ANALYSES To analyze MIP S-index and endurance we will use an electronic device employed by health professionals for the assessment and training of the inspiratory muscles in patients with dyspnea POWERbreathe K series KH2 HaB International Warwickshire United Kingdom POWERbreathe 2019

MIP assessment

Initially the patients will be instructed and familiarized with the device and the maneuver that will be performed in which they will inhale against a closed airway with prior warming of the inspiratory muscles and learning of the technique MIP will be measured with the patients in a seated position They will be encouraged to slowly exhale all the air and from the residual volume RV perform a maximum inspiration A nose clip and a mouthpiece with a bacteriological and viral filter which must be well attached to the patients mouth will be used Three maneuvers with 1-min rest intervals will be performed and recorded Values must vary by less than 20 and the highest one will be selected

The MIP result displayed in the software corresponds to the highest 1-second mean pressure achieved during the maneuver measured at 50 Hz This measure reflects the pressure developed by the respiratory muscles plus the elastic recoil pressure of the respiratory system in the residual volume and is an index of global respiratory output rather than a direct measure of the contractile properties of the inspiratory muscles This result will be used to monitor the influence of IMT

The MIP values predicted for the Brazilian population have been published by several authors and the main equations validated for Brazilians are the ones by Neder et al Costa et al Simões et al and Pessoa et al The present proposal will predict MIP values through the equation of Neder et al in which

For men MIP cmH2O 1553 - 080 x age
For women MIP cmH2O 1104 - 049 x age

S-Index assessment

The S-Index is a measure of the dynamic strength of the inspiratory muscles and is derived from the result of the peak inspiratory flow registered by the devices sensors in each incursion using a patented algorithm Unlike the isometric measurement MIP in this assessment the individual will perform the inspiratory maneuver through a valve with free air passage Inspiratory muscle strength is calculated across the entire range of inspired lung volume The result of the strength index is classified based on the normal values predicted for the population studied These values which are recorded in cmH2O are individually calculated by the software Breathelink POWERbreathe Warwickshire United Kingdom using information from the patients profile As patient learning has been described regarding this parameter ten maneuvers will be performed in sequence without rest between attempts and the best result will be considered The technique for measuring dynamic strength is similar to that of MIP in which the patient must be seated with a nose clip occluding the air passage through the nostrils and a mouthpiece with a bacteriological and viral filter tightly coupled to the mouth

Inspiratory muscle endurance assessment

The tool POWERbreath K series POWERbreathe International Ltd Warwickshire United Kingdom enables the performance of endurance tests Silva et al 2016 Endurance is the ability to sustain a specific task over time The training load will be predetermined manually and introduced gradually over the first five breaths as this is a constant load test at 60 of the MIP value obtained from each patient The patient will be instructed to breathe as long as possible until no breath can be fully completed that is until respiratory fatigue occurs In the absence of respiratory fatigue the maximum evaluation limit will be seven minutes when the test is successfully completed The results of resistance training will be recorded in the software and include the following parameters Peak Inspiratory Flow ls Training Load cmH2O Average Power Watts Average Inspired Volume l and Energy Joules

INTERVENTION CARDIOPULMONARY REHABILITATION All groups will undergo the rehabilitation protocol comprised of muscle strengthening and aerobic training Muscle strengthening will be achieved through a sit and stand up from a chair routine abduction of upper and lower limbs and rowing three sets of 10 repetitions of each exercise will be performed Elastic tubes will be used with elasticity defined by color and indicating the greatest resistance the participant can endure with an effort between 4 and 8 on the OMNI-RES scale for perceived exertion Tiggemann et al 2010 Lagally Robertson 2006 Ramos et al 2014 Ribeiro 2021 In addition aerobic exercise will be performed through walking on flat terrain for five minutes in the first week 10 minutes in the second and 20 minutes in subsequent weeks with intensity between 40-60 of the reserve heart rate and respecting the patients symptoms Spilmanns et al 2021 Barker-Davies 2020 Ribeiro 2021 3611 Aerobic exercise intensity calculation

Aerobic training intensity will be calculated by the modified BORG subjective exertion scale maintaining a score between 6 and 7 - with the progression respecting the patients symptoms - and by the reserve heart rate

Target intensity HRmax - HRrest 04 a 06 HRrest First maximum HR is determined using the Karvonen formula 220 - age KARVONEN 1957

On the day of the first assessment the resting HR will be determined after the participant has been at rest for five minutes in a sitting position in an environment at 22 oC By determining HRmax and HRrest it will be possible to calculate the target range for each participant For individuals using beta blockers the modified BORG subjective exertion scale will be used maintaining a score between 6 and 7 The intensity and progression will be based on the individual reports of the symptoms of all patients Spilmanns et al 2021 Barker-Davies 2020 Ribeiro 2021

362 INSPIRATORY MUSCLE TRAINING Patients from the TG will undergo IMT for six weeks performing two sets of 30 repetitions daily using the device POWERbreathe classic medic POWERbreathe International Ltd Southam United Kingdom MIP will be measured in all patients before the intervention as described earlier and pa-tients will exercise at 40 MIP in the first week and 60 MIP in the subsequent five weeks The patients will be instructed to inhale using the diaphragm muscle trying to expand the rib cage to avoid using accessory muscles Turqueto et al 2021

A nose clip will be used to ensure patients breathe exclusively through the training device All patients will have their training sessions supervised by the same physical therapist and will be encouraged to maintain their usual activities during the protocol Turqueto et al 2021

Control patients CG who will undergo muscle strengthening and aerobic training during pulmonary rehabilitation will receive the same IMT intervention using POWERbreathe classic medic POWERbreathe International Limited Southam United Kingdom soon after completion of the 6-week experimental protocol if the study has satisfactory results

STATISTICAL ANALYSIS Data normality will be tested through the Shapiro-Wilk test To analyze the differences between groups the t-test will be used for parametric data and the Wilcoxon test for non-parametric data Bilateral tests will be performed using a significance level set at 5 p 005 Data will be analyzed using the SPSS 80 software and the results expressed as mean standard deviation or median and interquartile range

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None